Solid Tumor Malignancies Clinical Trial
Official title:
Phase I Study of Autologous Lymphocyte Infusions After Radiation Therapy to Mitigate Radiation Induced Lymphopenia and Enhance Immune Reconstitution in Patients With Solid Tumor Malignancies
Verified date | March 2024 |
Source | M.D. Anderson Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical research study is to learn if giving autologous lymphocyte infusions to patients who are receiving chemotherapy and radiation for non-small cell lung cancer or esophageal cancer is safe and effective.
Status | Active, not recruiting |
Enrollment | 25 |
Est. completion date | February 2, 2027 |
Est. primary completion date | February 2, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Histologically or cytologically documented NSCLC or esophageal cancers Stage II-IVA disease where definitive chemoradiation is the standard of care Age 18 Exclusion Criteria: Prior radiotherapy to the chest Life expectancy<6 months Any systemic therapy, aside from standard of care immunotherapy, that is planned to be administered prior to 6 weeks after ALI. Pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | M D Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
M.D. Anderson Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the absolute lymphocyte counts in lung and esophageal cancer patients who had undergone chemoradiation. (CRT) | The primary outcome is the change between the two measures, i.e., absolute lymphocyte counts at week 6 (+/- 14 days) minus baseline ALC, referred as ALC change. Recently, we reviewed 755 patients with stage I-III esophageal carcinoma who received concurrent CRT with or without surgery in 2004-2015 [1]. The means of the absolute lymphocyte counts were 1,570 cells/µL (SD=610) and 980 cells/µL (SD=600) at based line and at the first follow-up visit post-CRT, respectively. We incorporate this clinical evidence in our sample size justification. | Baseline to 6 weeks | |
Secondary | To evaluate the feasibility of ALI in patients who had undergone chemoradiation. | The number of patients who fail to complete the planned ALI treatment (i.e., inability to collect cell dose or receive cell infusion), will be counted and used as the summary of feasibility for this study. We will evaluate the feasibility of this study for future research and, it will be considered as feasible if less than 5 patients fail planned ALI treatment, while it will be stopped if 10 or more patients fail the planned ALI treatment during any time of the trial. The primary outcome of ALC will be summarized by means and standard deviations along with box-and-whisker plots. | Baseline to 6 weeks | |
Secondary | To evaluate the safety of ALI in patients who had undergone chemoradiation. | The method of Thall, Simon and Estey (1995) will be used for toxicity monitoring for this study. Denote the probability of toxicity by PT. We assume a priori, PT ~ beta (0.2, 1.8).
We will stop the arm if Pr(PT> 0.1 | data)>0.80. That is, we will stop the arm for new patient enrollment if at any time during the study, we determine that there is more than 80% chance that the toxicity rate is more than 10%. This toxicity stopping rule will be applied starting from the 10th patient. |
Baseline to 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05085548 -
ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
|
Phase 1 | |
Completed |
NCT01924689 -
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
|
Phase 1 | |
Completed |
NCT00310895 -
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
|
Phase 1 | |
Completed |
NCT01183364 -
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
|
Phase 1 | |
Terminated |
NCT00195156 -
Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies
|
Phase 1 | |
Terminated |
NCT01290380 -
A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies
|
Phase 1 | |
Terminated |
NCT01118819 -
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
|
Phase 1 |